Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/114169
DC FieldValueLanguage
dc.contributor.authorRaza, Faisal-
dc.contributor.authorEvans, Lauren-
dc.contributor.authorMotallebi, Mahzad-
dc.contributor.authorZafar, Hajra-
dc.contributor.authorPereira-Silva, Miguel-
dc.contributor.authorSaleem, Kalsoom-
dc.contributor.authorPeixoto, Diana-
dc.contributor.authorRahdar, Abbas-
dc.contributor.authorSharifi, Esmaeel-
dc.contributor.authorVeiga, Francisco-
dc.contributor.authorHoskins, Clare-
dc.contributor.authorPaiva-Santos, Ana Cláudia-
dc.date.accessioned2024-03-25T08:59:29Z-
dc.date.available2024-03-25T08:59:29Z-
dc.date.issued2023-
dc.identifier.issn17427061pt
dc.identifier.urihttps://hdl.handle.net/10316/114169-
dc.description.abstractPancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled as incurable. Chemotherapy continues to be the most popular treatment yet yields a very poor prognosis. The main barriers such as inefficient drug penetration and drug resistance, have led to the development of drug car- rier systems. The benefits, ease of fabrication and modification of liposomes render them as ideal future drug delivery systems. This review delves into the versatility of liposomes to achieve various mechanisms of treatment for pancreatic cancer. Not only are there benefits of loading chemotherapy drugs and target- ing agents onto liposomes, as well as mRNA combined therapy, but liposomes have also been exploited for immunotherapy and can be programmed to respond to photothermal therapy. Multifunctional lipo- somal formulations have demonstrated significant pre-clinical success. Functionalising drug-encapsulated liposomes has resulted in triggered drug release, specific targeting, and remodeling of the tumor envi- ronment. Suppressing tumor progression has been achieved, due to their ability to more efficiently and precisely deliver chemotherapy. Currently, no multifunctional surface-modified liposomes are clinically approved for pancreatic cancer thus we aim to shed light on the trials and tribulations and progress so far, with the hope for liposomal therapy in the future and improved patient outcomes.pt
dc.language.isoengpt
dc.publisherElsevierpt
dc.relationSFRH/BD/148771/2019pt
dc.relationFCT - grant 2021.05914.BDpt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt
dc.subjectLiposomespt
dc.subjectDrug deliverypt
dc.subjectControlled releasept
dc.subjectNanocarrierpt
dc.subjectStroma remodelingpt
dc.subjectCancerpt
dc.subjectIntratumorpt
dc.titleLiposome-based diagnostic and therapeutic applications for pancreatic cancerpt
dc.typearticle-
degois.publication.firstPage1pt
degois.publication.lastPage23pt
degois.publication.titleActa Biomaterialiapt
dc.peerreviewedyespt
dc.identifier.doi10.1016/j.actbio.2022.12.013pt
degois.publication.volume157pt
dc.date.embargo2023-01-01*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.orcid0000-0001-9772-4504-
crisitem.author.orcid0000-0002-1041-0068-
crisitem.author.orcid0000-0003-2710-6000-
Appears in Collections:FFUC- Artigos em Revistas Internacionais
Files in This Item:
Show simple item record

Page view(s)

16
checked on May 8, 2024

Download(s)

1
checked on May 8, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons